TM Owner TOLMAR Inc.
Jatenzo 237mg Capsule
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Jatenzo 237 mg capsules contain testosterone undecanoate, an androgen, in an oral soft-gel formulation absorbed largely through the lymphatic system rather than straight through the liver.
- Jatenzo is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone - primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (pituitary or hypothalamic causes) - confirmed by laboratory testing.
- Safety and efficacy have NOT been established in men with age-related hypogonadism, and Jatenzo is not approved for males under 18 years.
- The usual starting dose is 237 mg by mouth twice daily, once in the morning and once in the evening, always taken with food; the dose is then titrated between 158 mg and 396 mg twice daily according to a serum testosterone level drawn about six hours after the morning dose, at least seven days after starting or changing the dose.
- Jatenzo is a Schedule III controlled substance and is currently labelled by TOLMAR Inc., not Clarus Therapeutics.
Side Effects
- The adverse reactions reported in more than 2% of men taking Jatenzo are polycythaemia and increased haematocrit, diarrhoea, dyspepsia, belching, nausea, peripheral oedema (swollen ankles or feet), headache, prostate enlargement and hypertension.
- IMPORTANT LABEL CHANGE: the BOXED WARNING about increases in blood pressure was REMOVED from the Jatenzo label in July 2025 - elevated blood pressure remains a full Warning and Precaution, with ambulatory monitoring showing an average rise of 4.9/2.5 mmHg from baseline after four months, and Jatenzo is not recommended in men with uncontrolled hypertension.
- Seek urgent care for chest pain, breathlessness, one-sided weakness or slurred speech, a painful or prolonged erection, or pain and swelling in a leg.
- Report worsening urinary symptoms, breast tenderness, mood changes or persistent swelling, and have your blood pressure checked regularly throughout treatment.
Precautions & Warnings
- Jatenzo is contraindicated in men with breast cancer or known or suspected prostate cancer, in pregnant women because testosterone may cause fetal harm, and in anyone with known hypersensitivity to the product.
- Blood pressure must be measured before and during treatment and should be controlled first.
- Haematocrit should be checked before starting, about every three months during the first year and then yearly, and treatment stopped if it rises too high.
- Men should be evaluated for prostate cancer before starting and monitored during treatment, and watched for worsening benign prostatic hyperplasia.
- Testosterone is a Schedule III controlled substance with a risk of abuse and dependence at supratherapeutic doses, often taken with other anabolic steroids; misuse has caused heart attack, stroke, heart failure, depression and aggression.
- Jatenzo must always be taken with food, because absorption is poor without it.
- Women and children must not take or handle the capsules.
Avoid Interactions
- Interactions that INCREASE risk: warfarin and other oral anticoagulants - testosterone can raise the INR and bleeding risk, so the INR needs more frequent monitoring; corticosteroids such as prednisone, which add to fluid retention and ankle swelling, particularly in heart, kidney or liver disease; and other medicines that raise blood pressure, whose effect can be additive with Jatenzo's own blood-pressure rise.
- Testosterone may lower blood glucose and reduce insulin requirements in men with diabetes, so glucose should be monitored and the insulin or tablet dose may need lowering.
- Jatenzo must never be combined with other testosterone products or with anabolic steroids obtained without prescription.
- Limit alcohol because of the added liver and blood-pressure burden.
- Tell every prescriber, including dentists and surgeons, that you take a Schedule III androgen, and disclose all prescription medicines, over-the-counter products, herbal remedies and supplements before starting.
References
Frequently Asked Questions
Jatenzo (testosterone undecanoate) is an oral capsule used for testosterone replacement in adult men whose bodies make little or no testosterone because of testicular, pituitary or hypothalamic disease. It is not approved for age-related low testosterone or for males under 18, and it is a Schedule III controlled substance.
Take Jatenzo (testosterone undecanoate) twice daily with food, once in the morning and once in the evening; food is essential for absorption. The usual starting dose is 237 mg twice daily, adjusted between 158 mg and 396 mg using a testosterone blood level taken six hours after the morning dose.
The commonest side effects of Jatenzo (testosterone undecanoate) are a rise in red cell concentration and haematocrit, diarrhoea, indigestion, belching, nausea, swollen ankles, headache, prostate enlargement and raised blood pressure. Get urgent help for chest pain, breathlessness, one-sided weakness, slurred speech or a prolonged erection.
Do not use Jatenzo (testosterone undecanoate) if you have breast cancer or known or suspected prostate cancer, and never combine it with other testosterone products or anabolic steroids. Never take it on an empty stomach. Take care with warfarin, corticosteroids, insulin and blood-pressure medicines.
No. The boxed warning about increases in blood pressure was removed from the Jatenzo (testosterone undecanoate) label in July 2025. Raised blood pressure remains a key warning: it rose by about 4.9/2.5 mmHg over four months, and Jatenzo is not recommended in uncontrolled hypertension.
Serum testosterone is measured about six hours after the morning Jatenzo (testosterone undecanoate) dose, at least seven days after starting or changing it, to set the dose. Haematocrit is checked before treatment, every three months in the first year, then yearly. Prostate health is also monitored.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
